OREANDA-NEWS. April 20, 2015. Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, today announces that a poster exemplifying the Company's Moditope® immunotherapy platform has been accepted for presentation at the American Association for Cancer Research Annual Meeting (AACR) in Philadelphia, Pennsylvania.

The AACR Annual Meeting highlights the latest, most exciting discoveries in every area of cancer research and provides a unique opportunity for investigators from all over the world to meet, interact, and share their insights. This year's meeting theme - "Bringing Cancer Discoveries to Patients" - underscores the vital and inextricable link between discovery and treatment, and it reinforces the fact that research underpins all the progress being made in the field toward cancer cures.

The title, timing and location of the poster presentation is as follows:

Abstract:

1348

Title:

CD4 T cells targeting citrullinated vimentin reject advanced tumors

Day/Date:

Monday 20 April 2015

Session Time:

8:00am to 12:00pm EDT

Location:

Section 13, Poster Board Number 18

The presentation abstract can be accessed through the AACR website:

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=0cf4d7d6-5069-4032-996a-84e0ceb978ef&cKey=c7d3f1c7-31d2-4063-b18e-40db764186e6&mKey=%7b19573A54-AE8F-4E00-9C23-BD6D62268424%7d